DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR ® (SABER ®-Bupivacaine) Covering the United States

CUPERTINO, Calif., May 8, 2017 - DURECT Corporation (Nasdaq: DRRX) today announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NYSE: NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.
Sandoz is a global leader in driving sustainable access to high-quality healthcare.  Sandoz's differentiated product portfolio includes a range of state-of-the-art technologies, formulations and devices. In the U.S., Sandoz Inc. has a dedicated hospital sales and marketing organization, with expertise and relationships, which will be employed to deliver POSIMIR to the market.
Read more: DURECT Corporation ( DRRX )

Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value

Immunomedics and Seattle Genetics reach mutual agreement to dissolve previously agreed upon Exclusive Global Licensing Agreement, returning Sacituzumab Govitecan (IMMU-132) to Immunomedics
Unwinding of the deal releases both companies from all material obligations subject to Court approval; Seattle Genetics maintains its existing equity stake in the Company; Exercise period of IMMU warrants held by Seattle Genetics shortened substantially
Immunomedics announces completion of $125 million private placement of Series A-1 Convertible Preferred Stock to institutional investors; capital will support execution of plan to file for accelerated approval for IMMU-132
Read more: Immunomedics Inc ( IMMU )

Ceapro Inc. Demonstrates First Water Soluble Solid Nanodispersion Formulation of CoQ10 Utilizing its PGX Enabling Technology

Announces positive results from the first phase of a project to develop a functional energy drink at the 16th European Meeting on Supercritical Fluid Technologies held in Lisbon, Portugal
EDMONTON, ALBERTA--(May 4, 2017) - Ceapro Inc.(TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion of the first development phase of a project entitled, "Beta glucan with coenzyme Q10 ("CoQ10"): A novel ingredient for functional beverages." This project included two studies, which were conducted at the University of Alberta by Dr. Feral Temelli's team along with Ceapro researchers.
Read more: Ceapro Inc ( CZO )

Pieris Pharmaceuticals and AstraZeneca Collaborate to Develop and Commercialize Anticalin-Based Inhaled Treatments for Respiratory Diseases

BOSTON, MA--(May 03, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)
Pieris to receive $57.5 million USD in upfront and near-term milestone payments
Pieris has the potential to receive development-dependent milestones and eventual commercial payments for all products not exceeding $2.1 billion as well as tiered royalties
For programs co-developed by Pieris, the Company will be entitled to receive increased royalties or a gross margin share on worldwide sales, dependent on the level of investment to which Pieris commits
Read more: Pieris Pharmaceuticals Inc ( PIRS )

Microbix Consults with FDA Regarding Plans for Kinlytic(R) Urokinase

Project Activity Now Expected to Accelerate
TORONTO, ONTARIO--(May 1, 2017) - Microbix Biosystems Inc. (TSX:MBX) ("Microbix" or the "Company") a developer and marketer of biological products and technologies, announces that it has consulted with the U.S. Food and Drug Administration (the "FDA") regarding the Company's plans to return its thrombolytic biologic drug, Kinlytic® Urokinase ("Kinlytic"), to the U.S. market.
Microbix believes the results of its consultation will accelerate its work to obtain financing, complete its re-launch program and then submit an application to FDA for re-approval in the U.S. market. The Company has already received expressions of interest to license or acquire Kinlytic and to provide full funding for its re-launch program. Following its consultation with FDA, the Company now intends to accelerate its work to conclude such an agreement. Microbix has also established that Kinlytic may be produced via contract manufacturing, a factor that should shorten the timeline of its return to market. The Company plans to retain a significant interest in the economics of Kinlytic following an agreement to enable its re-launch program.
Read more: Microbix Biosystems ( MBX )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker